RNA antisense oligonucleotide for intravitreal injection ( DrugBank: - )

2 diseases

ID	Disease name (Link within this page)	Number of trials
90	Retinitis pigmentosa	1
303	Usher syndrome	1

90. Retinitis pigmentosa

Clinical trials : 130 / Drugs : 180 - (DrugBank : 41) / Drug target genes : 49 - Drug target pathways : 109

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05085964 (ClinicalTrials.gov)	September 13, 2021	7/10/2021	An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retiniti ...	An Open-Label Extension Study to Evaluate the Safety and Tolerability of QR 421a in Subjects With Re ...	Retinitis Pigmentosa;Usher Syndrome Type 2	Drug: RNA antisense oligonucleotide for intravitreal injection	ProQR Therapeutics	NULL	Enrolling by invitation	18 Years	N/A	All	20	Phase 2	United States;Canada;France

Clinical trials : 9 / Drugs : 13 - (DrugBank : 0) / Drug target gene : 0 - Drug target pathway : 0

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05085964 (ClinicalTrials.gov)	September 13, 2021	7/10/2021	An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retiniti ...	An Open-Label Extension Study to Evaluate the Safety and Tolerability of QR 421a in Subjects With Re ...	Retinitis Pigmentosa;Usher Syndrome Type 2	Drug: RNA antisense oligonucleotide for intravitreal injection	ProQR Therapeutics	NULL	Enrolling by invitation	18 Years	N/A	All	20	Phase 2	United States;Canada;France